Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $63 at Jefferies
March 5, 2025 5:21 AM ESTJefferies analyst Amy Li lowered the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $63.00 (from $64.00) while maintaining a Buy rating.
The analyst comments "BHVN provided program updates during Q4 earnings. Our thoughts - BHV-1300: While we see +'ves in data (~80% median... More
Piper Sandler Reiterates Overweight Rating on Biohaven Pharmaceutical Holding (BHVN)
March 3, 2025 12:35 PM ESTPiper Sandler analyst Christopher J. Raymond reiterated an Overweight rating and $76.00 price target on Biohaven Pharmaceutical Holding (NYSE: BHVN).
The analyst comments "Remain OW rated on BHVN shares following a Q424 update and the announcement of additional P1 MAD data for IgG... More
